We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01365000
First Posted: June 3, 2011
Last Update Posted: October 15, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
The is an assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects.

Condition Intervention Phase
Healthy Drug: NKTR118 Formulation 1 Drug: NKTR118 Formulation 2 Drug: NKTR118 Formulation 3 Drug: NKTR118 Formulation 1a Drug: NKTR118 Formulation 3a Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase I, Open-label, Randomized, Balanced, Single-dose, Two-Part Study to Assess the Relative Bioavailability of NKTR-118 in Three Formulations Under Fasted (3-Way Crossover) and Fed (2-Way Crossover) Conditions in Male and Non-fertile Female Subjects

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Pharmacokinetics after a dose of NKTR-118 25 mg by assessment of (Cmax) [ Time Frame: day-1 to day 3 ]
  • Pharmacokinetics after a dose of NKTR-118 25 mg by assessment of time to Cmax (tmax) [ Time Frame: day-1 to day 3 ]
  • Pharmacokinetics after a dose of NKTR-118 25 mg by assessment of half-life (t1/2λz) [ Time Frame: day-1 to day 3 ]
  • Pharmacokinetics after a dose of NKTR-118 25 mg by assessment of area under concentration-time curve (AUC(0-t)) [ Time Frame: day-1 to day 3 ]
  • Pharmacokinetics after a dose of NKTR-118 25 mg by assessment of area from time zero (pre-dose) extrapolated to infinity (AUC). [ Time Frame: day-1 to day 3 ]

Secondary Outcome Measures:
  • Safety and tolerability of NKTR-118 following administration of a single oral doses of NKTR-118 of 3 different formulations during fed and fasted conditions by assessing adverse events [ Time Frame: Duration day -1 (Visit 2) to follow up (Visit 12) ]
  • Safety and tolerability of NKTR-118 following administration of a single oral doses of NKTR-118 of 3 different formulations during fed and fasted conditions by assessing Safety Laboratory values [ Time Frame: Duration day -1 (Visit 2) to follow up (Visit 12) ]
  • Safety and tolerability of NKTR-118 following administration of a single oral doses of NKTR-118 of 3 different formulations during fed and fasted conditions by assessing 12-Lead Electrocardiograms [ Time Frame: Duration day -1 (Visit 2) to follow up (Visit 12) ]
  • Safety and tolerability of NKTR-118 following administration of a single oral doses of NKTR-118 of 3 different formulations during fed and fasted conditions by assessing Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Duration day -1 (Visit 2) to follow up (Visit 12) ]
  • Concentration of NKTR-118 in plasma samples after drug intake during Fed condition [ Time Frame: Duration: Day 1 to day 4 at the 2 last inhouse stays ]

Enrollment: 21
Study Start Date: June 2011
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NKTR118 Formulation 1
Fasted
Drug: NKTR118 Formulation 1
Oral dose, 25 mg
Experimental: NKTR118 Formulation 2
Fasted
Drug: NKTR118 Formulation 2
Oral dose, 25 mg
Experimental: NKTR118 Formulation 3
Fasted
Drug: NKTR118 Formulation 3
Oral dose, 25 mg
Experimental: NKTR118 Formulation 1a
Fed
Drug: NKTR118 Formulation 1a
Oral dose, 25 mg
Experimental: NKTR118 Formulation 3a
FED
Drug: NKTR118 Formulation 3a
Oral dose, 25 mg

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provision of signed and dated, written informed consent prior to any study-specific procedures
  • Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating, and must be of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria:
  • Post-menopausal defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and with follicle stimulating hormone (FSH) levels in the laboratory defined post-menopausal range
  • Irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not tubal ligation
  • Volunteers must have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg
  • Volunteers must be able to understand and be willing to comply with study procedures, restrictions and requirements
  • Healthy male and non-fertile female volunteers ages 18 to 55 years inclusive, with suitable veins for cannulation or repeated venipuncture

Exclusion Criteria:

  • Any clinically significant disease or disorder (eg, cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the Investigator, may either put the healthy volunteer at risk because of participation in the study, or influence the absorption, distribution, metabolism, and excretion of drugs
  • Current smokers, those who have smoked or used nicotine products within the previous 3 months from the date of screening (Visit 1)
  • Plasma donation within 1 month of screening or any blood donation/blood loss >500 mL during the 3 months prior to screening or intention to donate blood or blood products during the study or within 3 months after the completion of the study
  • Positive screen for drugs of abuse, or cotinine (nicotine level above 400 ng/mL), at screening or admission and/or positive alcohol test at admission
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational product
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01365000


Locations
United States, Kansas
Research Site
Overland Park, Kansas, United States
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Mark Sostek, MD AstraZeneca
Principal Investigator: David Mathews, MD Quintiles, Inc.
  More Information

Additional Information:
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01365000     History of Changes
Other Study ID Numbers: D3820C00025
First Submitted: May 31, 2011
First Posted: June 3, 2011
Last Update Posted: October 15, 2014
Last Verified: October 2014

Keywords provided by AstraZeneca:
Phase 1
Pharmacokinetics
NKTR-118
fasting or fed state
cross-over study
AUC(0-t)
Cmax
tmax
QTcF Interval

Additional relevant MeSH terms:
Naloxegol
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents